We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Galapagos Enters Collaboration in Autoimmune Discovery Research

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Galapagos Enters Collaboration in Autoimmune Discovery Research"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

BioFocus, the service division of Galapagos, has announced three year collaboration in the field of autoimmune discovery research.

Under the terms of the agreement, BioFocus will expand its SilenceSelect® si-RNA based gene collection with an additional gene set, develop a dedicated cellular assay in the field of autoimmune disease, and use this assay to run a target discovery screen.

Further to the collaboration agreement, Galapagos will receive upfront fees and research and development funding and may receive milestone fees when certain drug discovery criteria are met.

Should all criteria on a target be achieved, total potential contract value for Galapagos may exceed € 2 million.

"This collaboration capitalizes on Galapagos' know-how in the autoimmune field and the strength of its target discovery platform.  We are delighted to be Boehringer Ingelheim's partner in this disease discovery program," said Onno van de Stolpe, CEO of Galapagos. 

"In this new collaboration, Galapagos is committed to delivering novel drug targets as the basis for developing novel therapies for unmet medical needs in autoimmune disease."